Recent Company News

• 04:51 AM ET Oct 29, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (82 total)

• 05:26 AM ET Oct 27, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (93 total)

• 06:48 AM ET Oct 24, 2025
  

  Eli Lilly reports findings from Phase 3 ADjoin extension trial of EBGLYSS in patients with moderate-to-severe atopic dermatitis ($821.04, 0.00)

• 04:23 AM ET Oct 24, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (78 total)

• 04:08 AM ET Oct 23, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (80 total)

• 04:25 AM ET Oct 20, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (65 total)

• 01:51 AM ET Oct 14, 2025
  

  Almirall initiated buy at Stifel (€12.00, 0.00)

• 03:55 AM ET Oct 01, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (51 total)

• 08:08 PM ET Sep 04, 2025
  

  Kaken Pharmaceutical announces Almirall obtains marketing authorization approval for Efinaconazole (¥3902.0000, -13)

• 10:12 PM ET Aug 20, 2025
  

  RBC Capital Markets transfers ALM.SM, BIOA.B.SS, FYB.GR, others